Lindonlight Collective

Lindonlight Collective accelerates multidisciplinary scientific breakthroughs for pediatric brain cancer through venture philanthropy. It funds high-risk/high-reward research projects globally, focusing on innovative therapeutics such as peptide-centric CAR-T cell therapy and novel small molecule inhibitors targeting pediatric low-grade gliomas. Its model enables foundational infrastructure development and cross-institutional collaboration. Early results include identification of new immunotherapeutic targets and the development of first-in-class therapies now approaching clinical trial initiation for related childhood cancers like neuroblastoma.